Abstract
In the present paper 25 known thermolysin inhibitors were docked into thermolysin using the Internal Coordinate Mechanics (ICM™) software. Pharmacophore models based on thermolysin binding modes and activity profiles were generated using the LigandScout™ program. The docking studies indicated that all 25 inhibitors coordinated the catalytic zinc in bidentate or monodentate geometry. A ‘three-point’ pharmacophore model was proposed which consisted of a hydrophobic group, a negative ionizable group and a hydrogen bond acceptor group. Finally the pharmacophore model has been tested against a small compound library containing 18 highly, moderately, less active as well as inactive compounds. The screening indicated that the pharmacophore model could, identify highly active compounds in front of inactive or less active ones.
Keywords: Thermolysin inhibitors, molecular docking, pharmacophore models, antibacterial drugs, antihypertensive drugs, thermolysin, Listeeria, Clostridium, Staphyloccus, Pseudomonas, Vibrio
Mini-Reviews in Medicinal Chemistry
Title:Binding Modes and Pharmacophore Modelling of Thermolysin Inhibitors
Volume: 12 Issue: 6
Author(s): M. T.H. Khan, Y. Wuxiuer and I. Sylte
Affiliation:
Keywords: Thermolysin inhibitors, molecular docking, pharmacophore models, antibacterial drugs, antihypertensive drugs, thermolysin, Listeeria, Clostridium, Staphyloccus, Pseudomonas, Vibrio
Abstract: In the present paper 25 known thermolysin inhibitors were docked into thermolysin using the Internal Coordinate Mechanics (ICM™) software. Pharmacophore models based on thermolysin binding modes and activity profiles were generated using the LigandScout™ program. The docking studies indicated that all 25 inhibitors coordinated the catalytic zinc in bidentate or monodentate geometry. A ‘three-point’ pharmacophore model was proposed which consisted of a hydrophobic group, a negative ionizable group and a hydrogen bond acceptor group. Finally the pharmacophore model has been tested against a small compound library containing 18 highly, moderately, less active as well as inactive compounds. The screening indicated that the pharmacophore model could, identify highly active compounds in front of inactive or less active ones.
Export Options
About this article
Cite this article as:
T.H. Khan M., Wuxiuer Y. and Sylte I., Binding Modes and Pharmacophore Modelling of Thermolysin Inhibitors, Mini-Reviews in Medicinal Chemistry 2012; 12 (6) . https://dx.doi.org/10.2174/138955712800493799
DOI https://dx.doi.org/10.2174/138955712800493799 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Altered Prolylcarboxypeptidase Expression and Function in Response to Different Risk Factors of Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments
Current Pharmaceutical Design An Overview on Cardiovascular Protective Effects of Catechins
Cardiovascular & Hematological Disorders-Drug Targets Fontan Circulation Might be Associated with Peripartum Cardiomyopathy: A Review of Mechanistic and Clinical Aspects
Current Cardiology Reviews Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson’s Disease
Central Nervous System Agents in Medicinal Chemistry Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Domperidone and Long QT Syndrome
Current Drug Safety Thyroid Hormones and Cardiovascular System: From Bench to Bedside
Current Drug Therapy Renal and Hepatic Transporter Expression in Type 2 Diabetic Rats
Drug Metabolism Letters Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Endothelin-1-Induced Signaling Pathways in Vascular Smooth Muscle Cells
Current Vascular Pharmacology Oxidative Stress and Endothelial Dysfunction: Say NO to Cigarette Smoking!
Current Pharmaceutical Design Meet Our Editor:
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cilostazol: A New Drug in the Treatment Intermittent Claudication
Recent Patents on Cardiovascular Drug Discovery Stress and Physical Inactivity: Two Explosive Ingredients for the Heart in COVID-19 Pandemic Times
Current Cardiology Reviews Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology Recent Advances in Targeted Therapy for Glioma
Current Medicinal Chemistry The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews Novel Insights into Complex Cardiovascular Pathologies using 4D Flow Analysis by Cardiovascular Magnetic Resonance Imaging
Current Pharmaceutical Design